JAK2 V617F
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (NCT05198960) | University Hospital, Brest | 2022-07-13 |
Track JAK2 V617F automatically
Every clearance here is in the API, with alerts when new ones post.